We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

2 hedge funds and large institutions have $177K invested in Akari Therapeutics in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 3 → 2 (-1)

34% less capital invested

Capital invested by funds: $269K → $177K (-$91.7K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$26K
2
Citadel Advisors
Citadel Advisors
Florida
-$10.2K
3
Citigroup
Citigroup
New York
-$1K
4
Wells Fargo
Wells Fargo
California
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$166K – – –
Citadel Advisors
2
Citadel Advisors
Florida
$9K -$10.2K -2 -50%
UBS Group
3
UBS Group
Switzerland
$2K – – –
AIG
4
American International Group
New York
$348 – – –
VKH
5
Virtu KCG Holdings
New York
– -$26K -4 Closed
Citigroup
6
Citigroup
New York
– -$1K – –
Wells Fargo
7
Wells Fargo
California
– -$1K – –

AKTX Hedge Fund Activity: Q2 2015 in Review

2 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2015, worth a combined $177K — down 34% from $269K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of AKTX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $26K sold.

  • 2 institutional investors held Akari Therapeutics (AKTX) as of Q2 2015, down from 3 in Q1 2015.
  • Funds reported $177K of Akari Therapeutics stock for Q2 2015, down 34% quarter-over-quarter.
  • 0 funds opened new Akari Therapeutics positions in Q2 2015 and 1 closed out, a net change of -1 holder.
  • The largest Akari Therapeutics seller in Q2 2015 was Virtu KCG Holdings, an estimated $26K sold.

Based on aggregated 13F filings for Q2 2015.